Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of AFP on DAA Response in HCV
NCT03402165Phase 4Unknown
- Start
- Jan 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sofosbuvir, ledipasvir, daclatasvir in hepatitis C (HCV). Status: unknown.
02
Drugs
sofosbuvirledipasvirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03402165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402165.